Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31903 in Advanced Solid Tumors
NCT05823285Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS31903 in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose at 24 months and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
QLS31903
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05823285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823285.